ArticlePloS one2014
Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Differences between physician and patient preferences for cancer treatments: a systematic review.BMC cancer · 2023Pooled it
- Quality of life versus length of life considerations in cancer patients: A systematic literature review.Psycho-oncology · 2019Pooled it
- Risk attitudes and value of hope: survey results from Japanese hematologists and oncologists treating patients with diffuse large B-cell lymphoma.Scientific reports · 2026Article
- Breast Cancer Patient Attitudes Towards Oncology Drug Costs in Ireland.Current oncology (Toronto, Ont.) · 2026Article
- Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.Journal of cancer research and clinical oncology · 2024Article
- A tailored approach to horizon scanning for cancer medicines.Journal of cancer policy · 2023Article
- Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study.ESMO open · 2021Article
- Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.BMC cancer · 2021Article
- Therapy preferences in melanoma treatment-Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease.Cancer medicine · 2020Article
- Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.Patient preference and adherence · 2020Article
- Preferences of Canadian patients and physicians for adjuvant treatments for melanoma.Current oncology (Toronto, Ont.) · 2019Article
- Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center.Melanoma research · 2019Article
- In Reply.Deutsches Arzteblatt international · 2019Article
- Approaches to decision-making among late-stage melanoma patients: a multifactorial investigation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Article
- Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.Patient preference and adherence · 2017Article
- Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology.Advances in therapy · 2016Article
- Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands.Journal of cancer research and clinical oncology · 2016Article
- Access to new cancer medicines in Australia: dispelling the myths and informing a public debate.Journal of pharmaceutical policy and practice · 2016Article
- Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment.Cancer nursingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew melanoma therapies, like e.g. ipilimumab, improve survival. However, only a small subset of patients benefits while 60% encounter side effects. Furthermore, these marginal benefits come at a very high price of €110'000 per treatment. This study examines attitudes towards melanoma therapy options of physicians, healthy individuals and patients, their willingness to pay and preference of quality versus length of life.
methodsBased on findings from a focus group questionnaires were developed and pretested. After obtaining ethical approval and informed consent surveys were conducted in a total of 90 participants (n = 30 for each group). Statistical analyses were conducted using R.
findingsAttitudes vastly differed between healthy participants, physicians and melanoma patients. Whereas melanoma patients show a high willingness to endure side effects despite very small survival gains (down to 1 extra week) or even only hope with no survival benefit, healthy controls are more critical, while physicians are the most therapy adverse. Consequently, if given €100'000 and the free decision what to spend the money on the willingness to pay for therapy was much higher in the patient group (68%) compared to 28% of healthy controls and only 43% of the physicians, respectively. When lowering the amount of cash that could be received instead of ipilimumab to €50'000 or €10'000 to test price sensitivity 69% (+1%) and 76% (+8%) of melanoma patients, respectively, preferred ipilimumab over cash. When judging on societal spending even melanoma patients opted for spending on ipilimumab in only 21%.
conclusionThe judgment about the benefits of new treatment options largely differs between groups, physicians being the most critical against therapy. Price elasticity was low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.